crwepicks'  Instablog

Send Message
My company:
  • BJRI, PWRM, LNT, SGEN - Stocks To Watch For Monday Nov 15th From 0 comments
    Nov 14, 2010 1:23 PM | about stocks: BJRI, LNT, SGEN



    BJ's Restaurants, Inc. (Nasdaq:BJRI) announced that management will be presenting at the following investor conference in November:

    Citi 7th Annual Small/Mid Cap Conference at the Four Seasons at Mandalay Bay in Las Vegas, NV -- The presentation will begin at approximately 9:25 am (Pacific) on Wednesday, November 17, 2010. Interested parties may listen to the presentation at the Company's website located at The presentation can be accessed by clicking on the "Investors" link from the Company's home page followed by the "Presentation" link. An archive of the presentation will be available following the live presentation for 90 days.

    BJ's Restaurants, Inc. currently owns and operates 101 casual dining restaurants under the BJ's Restaurant & Brewery, BJ's Restaurant & Brewhouse or BJ's Pizza & Grill brand names. BJ's restaurants offer an innovative and broad menu featuring award-winning, signature deep-dish pizza complemented with generously portioned salads, appetizers, sandwiches, soups, pastas, entrees and desserts.




    PWRM pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 Medical works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops.

    Power3 Medical Products, Inc ., a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced recently that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3's diagnostic test, and focused on Power3's Alzheimer's disease blood serum biomarkers, test and clinical validation trials.

    "In preparation for commercialization, our objective at this meeting was to show how Power3's protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer's disease," said Dr. Ira L. Goldknopf, Power3's President and Chief Scientific Officer. "It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3's protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs."

    "We are pleased that our blood tests specifically diagnose Alzheimer's in patients, both pre- and post-treatment," said Helen R. Park, MS, Chief Executive Officer of Power3, "and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii."

    "We are within striking distance of realizing an Alzheimer's clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions," added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.

    Alzheimer’s disease is a progressive and fatal brain disease. Alzheimer’s destroys brain cells, causing memory loss and problems with thinking and behavior severe enough to affect work, lifelong hobbies or social life. Alzheimer’s gets worse over time, and it is fatal. Today it is the seventh-leading cause of death in the United States.

    Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.

    Power3 Medical Products, Inc., a bio-technology company, engages in the development and marketing of diagnostic tests in the fields of cancer, and neurodegenerative and neuromuscular diseases in the United States. The company was formerly known as Surgical Safety Products, Inc. and changed its name to Power3 Medical Products, Inc. in September 2003. Power3 Medical Products, Inc . was founded in 1992 and is based in The Woodlands, Texas.

    To learn more about PWRM visit:


    Quarterly dividends on preferred stock have been declared by the Board of Directors of Alliant Energy Corporation's (NYSE:LNT) utility subsidiaries.

    Wisconsin Power and Light Company Preferred Stock Dividends

    The Board of Directors of Wisconsin Power and Light Company (WPL) has declared dividends for its preferred stock shareowners of record on November 30, 2010. The dividends, which are payable on December 15, 2010, are as follows:

    $1.10 per share on the 4.40% series
    $1.125 per share on the 4.50% series
    $1.19 per share on the 4.76% series
    $1.20 per share on the 4.80% series
    $1.24 per share on the 4.96% series
    $1.55 per share on the 6.20% series
    $0.40625 per share on the 6.50% series

    Interstate Power and Light Company Preferred Stock Dividends

    The Board of Directors of Interstate Power and Light Company (IPL) has declared dividends for its preferred stock shareowners of record on November 30, 2010. The dividends, which are payable on December 15, 2010, are as follows:

    $0.523438 per share on the 8.375% Series B Cumulative Preferred Stock
    $0.443750 per share on the 7.10% Series C Cumulative Preferred Stock

    WPL and IPL are subsidiaries of Alliant Energy Corporation.

    Alliant Energy Corporation operates in electric and gas utility businesses in the United States.


    Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (, announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (NYSE:ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL. A summary of the presentations is below, and full abstracts can be accessed on the ASH website at

    Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases.


    Sign-Up For Free Stock Alerts At

    business card


    Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).


    Stocks: BJRI, LNT, SGEN
Back To crwepicks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.